✦ LIBER ✦

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group

✍ Scribed by Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 75 KB
Volume: 97
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.11290

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma.

METHODS

Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Cooperative Oncology Group Phase II study. Patients ranged in age from 27 to 79 years, with a median age of 59 years. The most common histology was leiomyosarcoma (54%). The grades of the tumors were high in 40%, moderate in 24% and low in 12%. Gemcitabine was given at a dose of 1250 mg/m^2^ as a 30‐minute infusion weekly for 3 weeks followed by 1 week of rest.

RESULTS

One of the 25 patients (4%) (90% confidence interval [90% CI], 0–18%) achieved a partial response lasting 8 months. The estimated overall median survival was 15 months. The 1‐year estimated survival rate was 63% (90% CI, 47–84%). The estimated median progression‐free survival (PFS) was 13 months with a 1‐year PFS rate of 56% (90% CI, 41–76%). Grade 3–4 toxicities (by CTC criteria) were observed in all 25 patients. No lethal toxicity (Grade 5) related to treatment was found.

CONCLUSIONS

The results of the current study demonstrated that gemcitabine given at this schedule and dose in this population of patients with advanced sarcoma had limited activity. Cancer 2003;97:1969–73. © 2003 American Cancer Society.

DOI 10.1002/cncr.11290

📜 SIMILAR VOLUMES

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera

Phase 2 trial of sorafenib in patients w

Phase 2 trial of sorafenib in patients with advanced urothelial cancer : A Trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J. R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Phase 2 trial of pemetrexed disodium and

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Matthew M. Cooney; George Wilding; Bruce J. Roth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND. There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelia

Phase II trial of trimetrexate for patie

Phase II trial of trimetrexate for patients with advanced gastric carcinoma : An Eastern Cooperative Oncology Group Study (E1287)

✍ Ramesh K. Ramanathan; Stuart Lipsitz; Robert F. Asbury; Raman Qazi; Bernard R. G 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

## BACKGROUND. A Phase II study was conducted to evaluate the response, duration of response, and duration of survival of patients with measurable gastric carcinoma treated with trimetrexate (TMTX) who had not had prior chemotherapy. ## METHODS. Thirty-three patients with unresectable or metast

Phase II trial of taxol in salivary glan

Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group

✍ Jill Gilbert; Yi Li; Harlan A. Pinto; Timothy Jennings; Merrill S. Kies; Paula S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Background: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers. the eastern cooperative oncology group (ecog) initiated a phase ii evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies. ## Methods: Chemo-nai

An eastern cooperative oncology group ph

An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.